Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Return on Capital Employed: 2016-2025

Historic Return on Capital Employed for Sunshine Biopharma (SBFM) over the last 7 years, with Sep 2025 value amounting to -0.26%.

  • Sunshine Biopharma's Return on Capital Employed fell 6.00% to -0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.26%, marking a year-over-year decrease of 6.00%. This contributed to the annual value of -0.26% for FY2024, which is 5.00% down from last year.
  • Sunshine Biopharma's Return on Capital Employed amounted to -0.26% in Q3 2025, which was up 0.59% from -0.26% recorded in Q2 2025.
  • Sunshine Biopharma's 5-year Return on Capital Employed high stood at -0.10% for Q3 2022, and its period low was -3.09% during Q1 2021.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.24% (2024), whereas its average is -0.50%.
  • In the last 5 years, Sunshine Biopharma's Return on Capital Employed crashed by 390bps in 2021 and then skyrocketed by 278bps in 2022.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Return on Capital Employed stood at -1.08% in 2021, then grew by 12bps to -0.96% in 2022, then surged by 74bps to -0.22% in 2023, then decreased by 2bps to -0.24% in 2024, then fell by 6bps to -0.26% in 2025.
  • Its Return on Capital Employed stands at -0.26% for Q3 2025, versus -0.26% for Q2 2025 and -0.24% for Q1 2025.